{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:17:27Z","timestamp":1794903447306,"version":"4.9.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"29","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Gilead Sciences, Inc","id":[{"id":"https:\/\/ror.org\/056546b03","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead and Merck KGaA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.1080\/14796694.2025.2591213","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:41:52Z","timestamp":1763718112000},"page":"3749-3757","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer"],"prefix":"10.1080","volume":"21","author":[{"given":"Friederike C.","family":"Althoff","sequence":"first","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Acker","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Koschade","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Heinzen","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Aguinarte","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Rost","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Schulte","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Winter","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]},{"name":"University Hospital MVZ GmbH","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Krause","sequence":"additional","affiliation":[{"name":"Clinical Research and Study Management","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Essen University Hospital, Clinic for Internal Medicine (Tumour Research) and Clinic for Urology","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]},{"name":"Goethe University","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]},{"name":"Goethe University","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital","place":["Frankfurt, Germany"]},{"name":"Goethe University","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2502931"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae021"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02965-0"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.041"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8592"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1297"},{"key":"e_1_3_7_14_1","unstructured":"Study of sacituzumab and zimberelimab for patients with resectable non-small cell lung cancer after surgery without complete disease clearance [Internet]. NCT06431633. [cited 2025 Jun 21]. Available from: https:\/\/clinicaltrials.eu\/trial\/study-of-sacituzumab-and-zimberelimab-for-patients-with-resectable-non-small-cell-lung-cancer-after-surgery-without-complete-disease-clearance\/"},{"key":"e_1_3_7_15_1","unstructured":"Study details | Study of novel treatment combinations in patients with lung cancer | ClinicalTrials.gov [Internet]. [cited 2025 Jun 30]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05633667#study-plan"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40291-025-00814-5"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321555"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.013"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03746-z"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.511"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.010"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8501"},{"key":"e_1_3_7_24_1","unstructured":"Study details | NCT06312137 | A study to assess efficacy and safety of pembrolizumab with or without sacituzumab tirumotecan (MK-2870) in adult participants with resectable non-small cell lung cancer (NSCLC) not achieving pathological complete response (pCR) (MK-2870\u2013019) | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06312137"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0230"},{"key":"e_1_3_7_26_1","unstructured":"Study details | NCT05687266 | phase III open-label first-line study of Dato-DXd in combination with durvalumab and carboplatin for advanced NSCLC without actionable genomic alterations | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05687266?term=D926NC00001&rank=1"},{"key":"e_1_3_7_27_1","unstructured":"Study details | NCT05609968 | study of pembrolizumab (MK-3475) monotherapy versus sacituzumab govitecan in combination with pembrolizumab for participants with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u226550% (MK-3475-D46) | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05609968"},{"key":"e_1_3_7_28_1","unstructured":"Study details | NCT03337698 | a study of multiple immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (morpheus- non-small cell lung cancer) | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03337698"},{"key":"e_1_3_7_29_1","unstructured":"Study details | NCT06422143 | pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in metastatic squamous non-small cell lung cancer (NSCLC) [MK-2870\u2013023] | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06422143"},{"key":"e_1_3_7_30_1","unstructured":"Study details | NCT04042701 | DS8201a and pembrolizumab in participants with locally advanced\/metastatic breast or non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04042701"},{"key":"e_1_3_7_31_1","unstructured":"Study details | NCT06899126 | Study of trastuzumab deruxtecan pembrolizumab and platinum-based chemotherapy in first-line HER2 overexpressing non-small cell lung cancer | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06899126"},{"key":"e_1_3_7_32_1","unstructured":"Study details | NCT04524689 | Tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with NSQ NSCLC | ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04524689"},{"key":"e_1_3_7_33_1","unstructured":"Study details | NCT04165070 | KEYMAKER-U01 substudy 01A: efficacy and safety study of pembrolizumab (MK-3475) with or without chemotherapy when used with investigational agents in treatment-na\u00efve participants with stage IV non-small cell lung cancer (NSCLC) (MK-3475-01A\/KEYMAKER-U01A)| ClinicalTrials.gov [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04165070"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.052"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.682"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2591213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2591213","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2591213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:31:21Z","timestamp":1794900681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2591213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":33,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025,12,8]]}},"alternative-id":["10.1080\/14796694.2025.2591213"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2591213","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}